Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract
Authors:
- Byung Soo KimBKByung Soo Kim
- Chul Won ChoiCCChul Won Choi
- Hee Yun SeoHSHee Yun Seo
- Hye Ryoung SeolHSHye Ryoung Seol
- Hwa Jung SungHSHwa Jung Sung
- In Sun KimIKIn Sun Kim
- Chul Yong KimCKChul Yong Kim
- Kwang Yoon JungKJKwang Yoon Jung
- Jun Suk KimJKJun Suk Kim
- 1 January 2006
- journal article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 47 (7) , 1265-1273
Abstract
We analysed the treatment outcome of localized extranodal NK/T cell lymphoma initially treated with CEOP-B chemotherapy based on the primary site of involvement (nasal cavity vs. upper aerodigestive tract) and treatment modality (chemotherapy vs. chemotherapy followed by radiotherapy. Forty-three patients newly diagnosed as extranodal NK/T cell lymphoma were analysed: 29 cases from nasal cavity/nasopharynx and 14 from upper aerodigestive tract. Twenty-six patients were treated with chemotherapy alone, while adjuvant radiotherapy was given to 17 patients. Overall response rate to front-line CEOP-B chemotherapy was 67.4% (29/43) and the complete remission (CR) rate was 44.2% (19/43). Median overall and disease-free survival was 26.87 months [95% confidence interval (CI) = 8.71 - 45.03] and 15.27 months (95% CI = 2.92 - 27.62). The responders (CR or partial response) to initial CEOP-B chemotherapy showed longer overall survival than non-responders (P = 0.0026). Local relapse was observed to be higher in the chemotherapy alone group compared to the chemoradiotherapy group. Adjuvant radiotherapy failed to improve survival; thus, the median disease-free survival of the chemotherapy and chemoradiotherapy groups was not different (P = 0.9101). There may be a tendency for better overall survival in group of upper aerodigestive tract lymphoma than the nasal cavity/nasopharynx group (P = 0.0643). However, front-line CEOP-B chemotherapy has a limited role and adjuvant radiotherapy failed to improve survival in localized extranodal NK/T cell lymphoma.Keywords
This publication has 25 references indexed in Scilit:
- Local tumor invasiveness is more predictive of survival than International Prognostic Index in stage IE/IIE extranodal NK/T-cell lymphoma, nasal typeBlood, 2005
- Extranodal nasal type NK/T-cell Lymphoma: Elucidating clinical prognostic factors for risk-based stratification of therapyEuropean Journal of Cancer, 2005
- Treatment Outcome of Angiocentric T-cell and NK/T-cell Lymphoma, Nasal Type: Radiotherapy Versus ChemoradiotherapyJapanese Journal of Clinical Oncology, 2005
- Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic IndexBlood, 2004
- Nasal and nasal-type natural killer/ T–cell lymphomaJournal of the American Academy of Dermatology, 1999
- Lymphoma of the nasal cavity and paranasal sinusesCancer, 1997
- CD56+ NK lymphomas:clinicopathological features and prognosisBritish Journal of Haematology, 1997
- Experience of radiotherapy in lethal midline granuloma with special emphasis on centrofacial T-cell lymphoma: a retrospective analysis covering a 34-year periodRadiotherapy and Oncology, 1996
- Report of the Workshop on Nasal and Related Extranodal Angiocentric T/Natural Killer Cell LymphomasAmerican Journal of Surgical Pathology, 1996
- Radiotherapy Compared to Chemotherapy as Initial Treatment of Angiocentric Centrofacial Lymphoma (Polymorphic Reticulosis)Acta Oncologica, 1993